[HTML][HTML] Selective chemical inhibition of PGC-1α gluconeogenic activity ameliorates type 2 diabetes

K Sharabi, H Lin, CDJ Tavares, JE Dominy… - Cell, 2017 - cell.com
K Sharabi, H Lin, CDJ Tavares, JE Dominy, JP Camporez, RJ Perry, R Schilling, AK Rines…
Cell, 2017cell.com
Summary Type 2 diabetes (T2D) is a worldwide epidemic with a medical need for additional
targeted therapies. Suppression of hepatic glucose production (HGP) effectively ameliorates
diabetes and can be exploited for its treatment. We hypothesized that targeting PGC-1α
acetylation in the liver, a chemical modification known to inhibit hepatic gluconeogenesis,
could be potentially used for treatment of T2D. Thus, we designed a high-throughput
chemical screen platform to quantify PGC-1α acetylation in cells and identified small …
Summary
Type 2 diabetes (T2D) is a worldwide epidemic with a medical need for additional targeted therapies. Suppression of hepatic glucose production (HGP) effectively ameliorates diabetes and can be exploited for its treatment. We hypothesized that targeting PGC-1α acetylation in the liver, a chemical modification known to inhibit hepatic gluconeogenesis, could be potentially used for treatment of T2D. Thus, we designed a high-throughput chemical screen platform to quantify PGC-1α acetylation in cells and identified small molecules that increase PGC-1α acetylation, suppress gluconeogenic gene expression, and reduce glucose production in hepatocytes. On the basis of potency and bioavailability, we selected a small molecule, SR-18292, that reduces blood glucose, strongly increases hepatic insulin sensitivity, and improves glucose homeostasis in dietary and genetic mouse models of T2D. These studies have important implications for understanding the regulatory mechanisms of glucose metabolism and treatment of T2D.
cell.com